Early Toxicity and Response Data From a Phase II Trial of Weekly Cetuximab, CBDCA, Paclitaxel, and Daily RT in Patients With Locally Advanced SCCHNM. Suntharalingam, Scott E. Strome, Julius Wolf et al.|International Journal of Radiation Oncology*Biology*Physics|2007Cited by 2